NCT05338450View on ClinicalTrials.gov

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple SclerosisInternuclear Ophthalmoplegia
Interventions
DRUG

Clemastine Fumarate

4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)

DRUG

Placebo

Placebo equivalent to experimental arm

Trial Locations (1)

1081 HV

RECRUITING

Amsterdam UMC, location VUmc, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER